▲ Peaking
Health
New weight loss pill that’s beating oral Ozempic
A new oral GLP-1 receptor agonist is demonstrating clinical performance in weight loss and glucose management, outperforming rival treatments.
2 trends tracked about this subject — the full history, oldest to newest below.
A new oral GLP-1 receptor agonist is demonstrating clinical performance in weight loss and glucose management, outperforming rival treatments.
Starting July 1, 2026, Medicare will cover GLP-1 weight-loss drugs for seniors, marking a significant expansion in obesity treatment access.